OC Oncoclínicas RJ


Evaluation of neoantigens in patients with NRAS-mutated melanoma


OC Oncoclínicas RJ

Principal investigator

Andreia Cristina de Melo



(21) 97138-0225 e (21) 2127-0281

Inclusion criteria

Confirmed histological diagnosis of cutaneous or mucosal melanoma, stage III or IV according to AJCC 8th edition, BRAF wild type.

Availability of tumor tissue for analysis (primary or metastatic samples) at any stage of your treatment.

Life expectancy of more than three months (according to the best medical judgment).

Patient must agree to have their clinical data collected anonymously and samples sent to a foreign laboratory (WIS)

Participant must agree to return to the site for additional peripheral blood collection, if necessary.

Exclusion criteria

Medical, psychiatric, cognitive or other conditions that may compromise the ability to understand the information provided (to the patient), the ability to provide informed consent, and adherence to the study protocol.

BRAF mutated melanomas


Tamires Almeida
Or share the link
Link copied to your desktop.